BDPT BIOADAPTIVES, INC.
Pharmaceutical Preparations · OTC · SEC CIK 1575142 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY230.2%
TTM net income YoY-106.3%
TTM EPS YoY—
Revenue 3-yr CAGR0.7%
Net income 3-yr CAGR—
Margins
Gross margin77.0%
Operating margin-3,610.9%
Net margin-8,805.9%
FCF margin—
EBITDA margin-3,587.7%
Returns
ROE—
ROA-2,510.3%
ROIC (approx.)—
Asset turnover0.29x
Leverage & solvency
Liabilities / assets4,703.4%
Debt / equity—
Current ratio0.02x
Interest coverage-2.42x
Cash quality & payout
Operating cash flow / net income0.17x
Accruals ratio-2,071.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $18,278 | $12,669 | $28,565 | $17,176 | $19,776 |
| Cost of revenue | $5,781 | $8,639 | $17,746 | $10,050 | $9,671 |
| Gross profit | $12,497 | $4,030 | $10,819 | $7,126 | $10,105 |
| SG&A expense | $820,508 | $335,306 | $101,478 | $254,119 | $268,268 |
| Operating income | -$1.04M | -$602,090 | -$228,921 | -$421,900 | — |
| Interest expense | $70,880 | $91,978 | $162,891 | $289,121 | $272,394 |
| Pretax income | -$1.56M | -$899,161 | — | — | — |
| Income tax | $0 | $0 | — | $0 | $0 |
| Net income | -$1.56M | -$899,161 | -$712,466 | -$895,570 | -$1.05M |
| EBITDA | -$1.04M | -$602,090 | — | — | — |
| EPS (basic) | — | -0.11 | -0.12 | — | — |
| EPS (diluted) | -0.15 | -0.11 | — | — | — |
| Weighted avg. shares (diluted) | 10.07M | 8.22M | — | — | — |
| Balance sheet | |||||
| Cash & equivalents | $158,445 | $137,470 | $60,776 | $25,405 | $82,936 |
| Short-term investments | $0 | $0 | $0 | $42 | $190 |
| Inventory | $44,706 | $19,115 | $15,281 | $8,877 | $4,750 |
| Current assets | $211,901 | $261,885 | $88,557 | $34,324 | $88,876 |
| PP&E, net | $14,000 | $0 | — | — | — |
| Intangibles | $14,000 | $0 | $15,441 | $2,990 | — |
| Total assets | $225,901 | $261,885 | $103,998 | $37,314 | $148,585 |
| Current liabilities | $2.36M | $1.73M | $1.75M | $1.49M | $1.24M |
| Total liabilities | $2.36M | $1.73M | $1.75M | $1.49M | $1.24M |
| Shareholders' equity | -$2.13M | -$1.46M | -$1.65M | -$1.45M | -$1.09M |
| Shares outstanding | 12.01M | 8.22M | 5.97M | 252.55M | 50.82M |
| Cash flow statement | |||||
| Operating cash flow | -$516,025 | -$249,517 | -$223,773 | -$227,259 | -$158,651 |
| Capital expenditure | $18,000 | $0 | — | — | — |
| Free cash flow | -$534,025 | -$249,517 | — | — | — |
| Investing cash flow | -$18,000 | $0 | — | — | — |
| Financing cash flow | $555,000 | $326,211 | $259,144 | $169,728 | $237,000 |
| Depreciation & amortization | $4,000 | $0 | — | — | — |
| Stock-based compensation | $28,670 | — | — | $0 | $163,900 |
Free plan shows the latest 5 periods; Pro shows all 10 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.